Clonazepam
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Lennox-Gastaut syndrome, akinetic and myoclonic seizures | Adults and children | Monotherapy or adjunctive | FDA Approved |
| Absence seizures (petit mal) — refractory to succinimides | Adults and children | Monotherapy or adjunctive (second-line) | FDA Approved |
| Panic disorder with or without agoraphobia | Adults | Monotherapy | FDA Approved |
Clonazepam is unique among commonly prescribed benzodiazepines in holding dual FDA-approved indications for both seizure disorders and panic disorder. Its long half-life (30–40 hours) allows twice-daily dosing for panic disorder and provides sustained anticonvulsant coverage. For seizures, clinicians should be aware that up to 30% of patients may experience loss of anticonvulsant efficacy within 3 months of treatment (tolerance), which may require dose adjustment or transition to alternative agents. For panic disorder, the optimal dose identified in fixed-dose clinical trials was 1 mg/day; higher doses (2–4 mg) were not consistently more effective and produced more adverse effects. Long-term efficacy beyond 9 weeks has not been systematically evaluated in controlled trials.
Restless legs syndrome (RLS): Used when dopaminergic agents are inadequate; taken at bedtime. Evidence quality: Moderate.
Acute mania (adjunctive): Short-term adjunct to mood stabilisers for agitation. Evidence quality: Moderate.
Tardive dyskinesia: May reduce involuntary movements. Evidence quality: Low.
REM sleep behaviour disorder: Widely used as first-line treatment; 0.5–2 mg at bedtime. Evidence quality: Moderate.
Essential tremor: Alternative to propranolol or primidone. Evidence quality: Low–Moderate.
Dosing
Seizure Disorders — Adults
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Lennox-Gastaut / akinetic / myoclonic seizures | 0.5 mg TID (1.5 mg/day) | Titrate to seizure control | 20 mg/day | Increase by 0.5–1 mg q3 days; divide into 3 equal doses Largest dose at bedtime if unequal division |
| Absence seizures — refractory to succinimides | 0.5 mg TID (1.5 mg/day) | Titrate to response | 20 mg/day | Second-line after ethosuximide or valproate failure Up to 30% may lose efficacy within 3 months (tolerance) |
Seizure Disorders — Paediatric
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Children <10 years or <30 kg | 0.01–0.03 mg/kg/day divided BID–TID | 0.1–0.2 mg/kg/day | 0.2 mg/kg/day | Do not exceed 0.05 mg/kg/day initially Increase by no more than 0.25–0.5 mg q3 days |
| Children ≥10 years or ≥30 kg | Same as adult dosing | Same as adult dosing | 20 mg/day | Follow adult titration schedule Safety for panic disorder not established <18 years |
Panic Disorder — Adults
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Panic disorder — initial treatment | 0.25 mg BID | 1 mg/day (target) | 4 mg/day | Increase to target 1 mg/day after 3 days; optimal dose in trials = 1 mg/day Higher doses (2–4 mg) not consistently more effective in trials (FDA PI) |
| Panic disorder — dose escalation if needed | From 1 mg/day | 1–4 mg/day in 2 divided doses | 4 mg/day | Increase by 0.125–0.25 mg BID q3 days Reassess long-term usefulness; efficacy beyond 9 weeks not established |
| Elderly patients | Low end of dosing range | Lowest effective dose | Individualise | Greater frequency of decreased hepatic/renal function Start cautiously; observe closely for sedation and confusion |
The FDA PI explicitly warns that up to 30% of patients initially responding to clonazepam for seizure control may lose anticonvulsant efficacy within 3 months. This is believed to reflect pharmacodynamic tolerance at the GABA-A receptor. When tolerance develops, dose adjustment may re-establish efficacy in some patients, but others will require transition to alternative anticonvulsants. This tolerance phenomenon is less clinically relevant for panic disorder, where treatment duration is typically shorter. Abrupt withdrawal in seizure patients may precipitate status epilepticus, and gradual taper with simultaneous substitution of another anticonvulsant is essential.
Pharmacology
Mechanism of Action
Clonazepam is a nitrobenzodiazepine that enhances the activity of GABA, the principal inhibitory neurotransmitter in the central nervous system. Like other benzodiazepines, it binds to the benzodiazepine site on the GABA-A receptor, increasing the frequency of chloride channel opening and producing neuronal hyperpolarisation. The resulting inhibitory tone produces anticonvulsant, anxiolytic, sedative, muscle-relaxant, and amnestic effects. Clonazepam also has serotonergic activity by increasing serotonin synthesis, which may contribute to its efficacy in panic disorder and movement disorders. Its potent anticonvulsant properties are attributed to both its high affinity for the benzodiazepine binding site and its long duration of action, maintaining sustained GABA-A receptor modulation across the interdose interval.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapidly and completely absorbed; bioavailability ~90%; Tmax 1–4 h; dose-independent pharmacokinetics | Predictable absorption across the dosing range (0.5–4 mg); no food effect concerns |
| Distribution | ~85% protein bound; Vd 1.5–4.4 L/kg; crosses placenta | Wide distribution into tissues; crosses blood-brain barrier readily; teratogenic in animals |
| Metabolism | Highly metabolised: nitroreduction to 7-amino derivative (major), then acetylation, hydroxylation, and glucuronidation; CYP3A4 involved in reduction and oxidation; <2% excreted unchanged | CYP3A4 inducers (phenytoin, carbamazepine, phenobarbital) reduce levels ~38%; azole antifungals may increase levels; does not induce its own metabolism |
| Elimination | t½ 30–40 h; paediatric clearance: 0.42–0.88 mL/min/kg (decreases with increasing body weight) | Long half-life allows BID dosing for panic disorder; hepatic impairment may prolong elimination (contraindicated in significant liver disease); renal impairment may cause metabolite accumulation |
Side Effects
Seizure Disorders
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Drowsiness | ~50% | Most common effect; dose-related; may diminish with continued use |
| Ataxia | ~30% | Significant impairment of gait and coordination; fall risk especially in children |
| Behaviour Problems | ~25% | More common in patients with pre-existing psychiatric disturbances and in children; includes aggression, hyperactivity, irritability |
Panic Disorder (Pooled Data, N=574)
| Adverse Effect | Incidence (Drug vs Placebo) | Clinical Note |
|---|---|---|
| Somnolence | 37% vs 10% | Dose-dependent (26% at <1 mg, up to 50% at 2–3 mg); leading cause of discontinuation (7%) |
| Adverse Effect | Incidence (Drug vs Placebo) | Clinical Note |
|---|---|---|
| Dizziness | 8% vs 4% | Dose-related; ranges from 5% (<1 mg) to 12% (2–3 mg) |
| URI / Respiratory Infection | 8% vs 4% | May reflect concurrent seasonal illness; not clearly dose-related |
| Depression | 7% vs 1% | Led to discontinuation in 4%; however HAM-D scores improved more on clonazepam than placebo |
| Fatigue | 7% vs 4% | Overlaps with somnolence; usually attenuates with continued use |
| Coordination Abnormal | 6% vs 0% | Dose-dependent (1% at <1 mg, 9% at ≥3 mg); significant fall risk |
| Ataxia | 5% vs 0% | Dose-dependent (2% at <1 mg, 8% at ≥3 mg); drives impairment assessment |
| Memory Disturbance | 4% vs 2% | Anterograde amnesia; dose-dependent |
| Sinusitis | 4% vs 3% | Not clearly drug-related |
| Nervousness | 3% vs 2% | May represent interdose or rebound anxiety |
| Dysmenorrhoea | 3% vs 2% | Female patients (N=334 clonazepam) |
| Constipation | 2% vs 2% | Dose-dependent (0% at <1 mg, 5% at 2–3 mg) |
| Dysarthria | 2% vs 0% | Dose-dependent (0% at <1 mg, 4% at 2–3 mg) |
| Intellectual Ability Reduced | 2% vs 0% | Dose-dependent; contributed to discontinuation in 1% |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Physical Dependence / Withdrawal Seizures / Status Epilepticus | Common with prolonged use | On abrupt discontinuation | Never stop abruptly; gradual taper essential; substitute alternative anticonvulsant simultaneously in seizure patients |
| Worsening of Tonic-Clonic Seizures | Reported in mixed seizure types | Variable | Add or increase appropriate anticonvulsant; consider discontinuing clonazepam if seizures worsen |
| Suicidal Thoughts / Behaviour (AED class warning) | ~0.43% (vs 0.24% placebo) across AEDs | As early as 1 week after starting | Monitor all patients; balance risk of suicidality vs untreated illness; report behaviours of concern immediately |
| Respiratory Depression | Dose-dependent; higher with opioid co-use | Variable | Use with extreme caution in COPD, sleep apnoea; discontinue if respiratory compromise occurs |
| Paradoxical Reactions (rage, aggression, psychosis) | Rare | Any time; more likely in children and elderly | Discontinue gradually; more common in patients with psychiatric history |
| Loss of Anticonvulsant Efficacy (Tolerance) | Up to 30% | Often within 3 months | Dose adjustment may help; consider transition to alternative anticonvulsant |
| Hypersalivation | Reported (seizure patients) | Early in treatment | Caution in patients with difficulty managing secretions; may contribute to aspiration risk |
Depression was reported in 7% of clonazepam-treated panic disorder patients vs 1% on placebo, and led to discontinuation in 4%. However, Hamilton Depression Rating Scale scores actually improved more in the clonazepam group, suggesting the reported “depression” may reflect subjective flattening of affect rather than true worsening of depressive illness. Nevertheless, clonazepam should be used with particular caution in patients with pre-existing depression, and prescription quantities should be limited to reduce suicide risk.
Drug Interactions
Clonazepam is metabolised primarily through nitroreduction and CYP3A-mediated pathways. CYP3A4 inducers significantly reduce clonazepam levels, which is clinically relevant when co-prescribing anticonvulsants. Clonazepam itself does not meaningfully alter the pharmacokinetics of phenytoin, carbamazepine, or phenobarbital, making it relatively straightforward to add to existing regimens from that perspective.
Monitoring
- Seizure FrequencySeizure diary; each visit
RoutineTrack seizure frequency, type, and severity. Up to 30% may develop tolerance within 3 months — reassess efficacy at each visit. - Sedation & CognitionEach visit during titration; q3 months
RoutineAssess for drowsiness, impaired coordination, memory disturbance, and reduced intellectual ability — all dose-dependent. - Mood & SuicidalityEach visit
RoutineFDA AED class warning: suicidal ideation risk ~0.43% vs 0.24% placebo. Depression reported in 7% of panic disorder trials. Monitor for emergence or worsening. - CBC & Liver FunctionPeriodically on long-term therapy
RoutinePeriodic blood counts and LFTs are advisable. Anemia, leukopenia, thrombocytopenia, and transaminase elevations have been reported. - Behaviour (Paediatric)Each visit
RoutineBehavioural problems in ~25% of seizure patients. Assess for aggression, irritability, hyperactivity, and paradoxical reactions — particularly in children. - Respiratory FunctionBaseline; ongoing in COPD/sleep apnoea
Trigger-basedHypersalivation and respiratory depression may compound secretion management difficulties. - Treatment Duration Reviewq3 months (panic); ongoing (seizures)
RoutinePanic disorder: efficacy beyond 9 weeks not established. Seizure: reassess for tolerance and ongoing benefit-risk. Document justification for continued use.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to benzodiazepines
- Significant liver disease (clinical or biochemical evidence)
- Acute narrow-angle glaucoma (may be used in open-angle glaucoma receiving appropriate therapy)
Relative Contraindications (Specialist Input Recommended)
- Pre-existing depression or psychosis — benzodiazepines may worsen depression; not for use without adequate antidepressant therapy
- Active substance use disorder — high abuse potential; requires documented risk-benefit analysis
- Mixed seizure disorders — may worsen or precipitate generalised tonic-clonic seizures
- Pregnancy — cleft palate and limb defects in rabbit studies; neonatal sedation and withdrawal with late-pregnancy use
- Porphyria — may have porphyrogenic effect
Use with Caution
- Elderly patients — start at low end of dosing range; increased fall and confusion risk
- Renal impairment — metabolites excreted renally; accumulation risk
- Compromised respiratory function — COPD, sleep apnoea; respiratory depression risk compounded by hypersalivation
- Patients who have difficulty handling secretions — hypersalivation is a recognised effect
Combined use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients with no adequate alternative. Use lowest doses for shortest duration.
Clonazepam exposes users to risks of abuse, misuse, and addiction. Assess each patient’s risk before prescribing and throughout treatment.
Continued use may lead to physical dependence. Abrupt discontinuation can precipitate status epilepticus (in seizure patients) or life-threatening withdrawal reactions. Use gradual taper and consider simultaneous substitution of alternative anticonvulsant.
Antiepileptic drugs, including clonazepam, approximately double the risk of suicidal thinking or behaviour (0.43% vs 0.24% placebo). The risk was observed as early as one week after starting treatment. Monitor all patients for emergence or worsening of depression, suicidal thoughts, or unusual behavioural changes.
Patient Counselling
Purpose of Therapy
Clonazepam is prescribed either to help control seizures or to reduce the frequency and severity of panic attacks. It works by calming excessive electrical activity in the brain. Because the body can become physically dependent on clonazepam, regular check-ups with your prescriber are essential. Never change your dose or stop taking clonazepam without medical supervision, as doing so can cause seizures or other dangerous withdrawal symptoms.
How to Take
For seizure disorders, clonazepam is usually taken three times daily in equally divided doses. For panic disorder, it is usually taken twice daily. Tablets should be swallowed whole with water. Orally disintegrating tablets (wafers) can be placed on the tongue and allowed to dissolve — water is not required. If doses are not equally divided, take the largest dose at bedtime to minimise daytime drowsiness.
Sources
- Klonopin (clonazepam) Tablets. Full Prescribing Information. Genentech USA, Inc. Revised 2017. FDA LabelPrimary source for all dosing (seizures and panic), adverse reaction tables (Tables 2-4), pharmacokinetic data, drug interactions, and contraindications.
- Klonopin (clonazepam) Tablets. Full Prescribing Information. Revised 2021 (updated boxed warnings). FDA Label (2021)Source for the updated three-part boxed warning (opioid co-use, abuse/misuse/addiction, dependence/withdrawal).
- Klonopin Medication Guide. FDA-approved patient labeling. Medication GuideFDA-approved patient communication tool covering key counselling points for clonazepam.
- Rosenbaum JF, Moroz G, Bowden CL. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. J Clin Psychopharmacol. 1997;17(5):390-400. DOIFixed-dose study (Study 1 in FDA PI) establishing 1 mg/day as the optimal dose for panic disorder, with 74% free of panic attacks vs 56% placebo.
- Moroz G, Rosenbaum JF. Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry. 1999;60(9):604-612. DOIFlexible-dose study (Study 2 in FDA PI); mean optimal dose 2.3 mg/day; 62% free of panic attacks vs 37% placebo.
- Mikkelsen B, Birket-Smith E, Bradt S, et al. Clonazepam in the treatment of epilepsy. A controlled clinical trial in simple absences, bilateral massive epileptic myoclonus, and atonic seizures. Arch Neurol. 1976;33(5):322-325. DOIEarly controlled trial demonstrating clonazepam efficacy in absence seizures, myoclonus, and atonic seizures.
- American Psychiatric Association. Practice Guideline for the Treatment of Patients with Panic Disorder. 2nd ed. APA; 2009. DOIPositions benzodiazepines as second-line for panic disorder after SSRIs/SNRIs; notes clonazepam’s long half-life as an advantage.
- Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults. Epilepsy Curr. 2016;16(1):48-61. DOIAES guideline context for benzodiazepine use in epilepsy; clonazepam is used for prophylaxis rather than acute SE management.
- Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85-95. DOIAASM best practice guide supporting clonazepam 0.5-2 mg at bedtime as the most widely used treatment for RBD.
- Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov. 2011;10(9):685-697. DOIReview of GABA-A receptor subtype pharmacology explaining benzodiazepine anticonvulsant, anxiolytic, and sedative effects.
- Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008;118(2):69-86. DOIComprehensive PK review covering clonazepam absorption, distribution (Vd 1.5-4.4 L/kg), metabolism, and paediatric clearance data.
- Patel SI, Birnbaum AK. Clonazepam. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. Updated May 13, 2023. NCBI BookshelfClinician-oriented review covering indications, dosing by population, serotonergic activity, and adverse effect management.